Crossref
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1667d ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: COVID-19, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
COVID-19Antirheumatic AgentsHumansCOVID-19 Drug TreatmentAntibodies, Monoclonal, Humanized
Stichwörter der Autor:innen
ActemraCOVID-19Olumiantbaricitinibdexamethasonedosageefficacytocilizumab
Substanzen
tocilizumabAntibodies, Monoclonal, HumanizedAntirheumatic Agents
Zitieren
APA
(2023). COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only). The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1667d
Vancouver
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only). The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1667d
BibTeX
@article{euvimed2023,
title = {COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only)},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1667d}
}
EUVIMED